학술논문
Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin
Document Type
Abstract
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia September 2018 18 Supplement 1:S208-S209
Subject
Language
ISSN
2152-2650